Servier acquires world rights to Pixuvri from CTI BioPharma.
Servier, announced the acquisition of Pixuvri from CTI BioPharma. Pixuvri is a treatment for adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma. Servier and CTI Biopharma completed an Asset Purchase Agreement which transferred worldwide rights of Pixuvri to Servier. Servier commercialized Pixuvri globally, in all countries where the drug was approved under an exclusive license from CTI BioPharma.
Comment: The conditional EU approval for Pixuvri was converted to a full approval on 13 June 2019.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.